Artwork

Content provided by TrialSite News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TrialSite News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Dr. Abribat talks Amolyt Pharma: Advance therapeutic peptides treat endocrine and metabolic diseases

16:17
 
Share
 

Manage episode 297076255 series 2949236
Content provided by TrialSite News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TrialSite News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We sit down and talk to Dr. Abribat about Amolyt Pharma, which is developing therapeutic peptides to treat rare endocrine and metabolic diseases. The company recently announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its experimental therapeutic peptide, AZP-3601, for a life-altering rare disease called hypoparathyroidism. This is Amolyt’s first clinical trial as a company. The trial, being conducted at sites in Europe, will test whether AZP-3601 will benefit patients with hypoparathyroidism by restoring lasting levels of calcium in their blood. Thierry Abribat, PhD can discuss why therapeutic peptides may provide better treatment options for patients with rare endocrine and metabolic diseases, the unmet need in hypoparathyroidism, AZP-360 and the ongoing trial

  continue reading

82 episodes

Artwork
iconShare
 
Manage episode 297076255 series 2949236
Content provided by TrialSite News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TrialSite News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We sit down and talk to Dr. Abribat about Amolyt Pharma, which is developing therapeutic peptides to treat rare endocrine and metabolic diseases. The company recently announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its experimental therapeutic peptide, AZP-3601, for a life-altering rare disease called hypoparathyroidism. This is Amolyt’s first clinical trial as a company. The trial, being conducted at sites in Europe, will test whether AZP-3601 will benefit patients with hypoparathyroidism by restoring lasting levels of calcium in their blood. Thierry Abribat, PhD can discuss why therapeutic peptides may provide better treatment options for patients with rare endocrine and metabolic diseases, the unmet need in hypoparathyroidism, AZP-360 and the ongoing trial

  continue reading

82 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide